Skip to main content
Advertisement
  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Education
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Online Sections
    • Neurology Video Journal Club
    • Diversity, Equity, & Inclusion (DEI)
    • Neurology: Clinical Practice Accelerator
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Neurology Future Forecasting Series
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit New Manuscript
    • Submit Revised Manuscript
    • Author Center

Advanced Search

Main menu

  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Education
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Online Sections
    • Neurology Video Journal Club
    • Diversity, Equity, & Inclusion (DEI)
    • Neurology: Clinical Practice Accelerator
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Neurology Future Forecasting Series
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit New Manuscript
    • Submit Revised Manuscript
    • Author Center
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Neurology Video Journal Club
  • Residents & Fellows

User menu

  • Subscribe
  • My Alerts
  • Log in

Search

  • Advanced search
Neurology
Home
The most widely read and highly cited peer-reviewed neurology journal
  • Subscribe
  • My Alerts
  • Log in
Site Logo
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Neurology Video Journal Club
  • Residents & Fellows

Share

April 06, 2015; 84 (14 Supplement) April 20, 2015

Multiple Sclerosis and Cancer (P1.119)

Deeya Gaindh, Katelyn Kavak, Barbara Teter, Muhammad Nadeem, Bianca Weinstock-Guttman
First published April 8, 2015,
Deeya Gaindh
5University At Buffalo Buffalo NY United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Katelyn Kavak
2Jacobs MS Treatment and Research Center Buffalo NY United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Barbara Teter
3New York State Multiple Sclerosis Consortium Buffalo NY United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Muhammad Nadeem
4University at Buffalo Buffalo NY United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bianca Weinstock-Guttman
1Jacobs MS Center and Pediatric MS Center of Excellence Buffalo NY United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Citation
Multiple Sclerosis and Cancer (P1.119)
Deeya Gaindh, Katelyn Kavak, Barbara Teter, Muhammad Nadeem, Bianca Weinstock-Guttman
Neurology Apr 2015, 84 (14 Supplement) P1.119;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Permissions

Make Comment

See Comments

Downloads
0

Share

  • Article
  • Info & Disclosures
Loading

Abstract

Objective: To investigate the prevalence of cancer in multiple sclerosis (MS) patients and to compare cancer prevalence in patients on disease modifying therapy (DMT) versus those who were DMT naive. Background: Few studies have studied whether MS alters the risk of cancer, with varying results. Previous studies suggest that the use of DMT does not increase the risk of cancer, however these studies did not investigate the use of long term DMT use and subsequent cancer risk. Method: Subjects were part of the New York State Multiple Sclerosis Consortium (NYSMSC) registry. Cancer prevalence and DMT use was determined at study enrollment. Independent samples t-tests and chi-square tests were utilized to determine if there were any differences between those who had cancer compared to those who did not. A binomial test was used to determine if the prevalence of cancer in our sample was significantly different from the North American cancer prevalence of 3.2[percnt] as reported by the National Cancer Institute (NCI). Results: Of the 9,240 subjects in our study, 133 (1.4[percnt]) reported having cancer. Those who had cancer were older (51.8±11.2) than those who did not (43.7±11.2, p<.001) and had a later age at MS symptom onset compared to those who did not have cancer (38.6±12.1 vs 32.6±9.9, p<.001). Furthermore, MS patients with cancer were more likely to be female (84.2[percnt] vs 74.2[percnt], p=.009). There were no difference in DMT use between those who had cancer and those who did not. Conclusions: Results show that cancer prevalence in our sample of patients with MS was lower than reported by the NCI (p<.001). There were no significant differences in prevalence between those using a DMT and those who did not. We are in the process of collecting more information about type of cancer, specifics on medication use, and family history.

Disclosure: Dr. Gaindh has nothing to disclose. Dr. Kavak has nothing to disclose. Dr. Teter has received research support from Biogen Idec, Teva Neuroscience, EMD Serono, Avanir Pharmaceuticals, Novartis, and Genzyme Corporation. Dr. Nadeem has nothing to disclose. Dr. Weinstock-Guttman has received personal compensation for activities with Biogen Idec, Teva Neuroscience, EMD Serono, Pfizer Inc., Novartis, Genzyme Corporation, Sanofi-Aventis Pharmaceuticals, Inc., Mylan, and Acorda Therapeutics. Dr. Weinstock-Guttma

Monday, April 20 2015, 2:00 pm-6:30 pm

  • Copyright © 2015 by AAN Enterprises, Inc.

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
  • Article
  • Info & Disclosures
Advertisement

Cutaneous α-Synuclein Signatures in Patients With Multiple System Atrophy and Parkinson Disease

Dr. Rizwan S. Akhtar and Dr. Sarah Brooker

► Watch

Related Articles

  • No related articles found.

Alert Me

  • Alert me when eletters are published
Neurology: 100 (22)

Articles

  • Ahead of Print
  • Current Issue
  • Past Issues
  • Popular Articles
  • Translations

About

  • About the Journals
  • Ethics Policies
  • Editors & Editorial Board
  • Contact Us
  • Advertise

Submit

  • Author Center
  • Submit a Manuscript
  • Information for Reviewers
  • AAN Guidelines
  • Permissions

Subscribers

  • Subscribe
  • Activate a Subscription
  • Sign up for eAlerts
  • RSS Feed
Site Logo
  • Visit neurology Template on Facebook
  • Follow neurology Template on Twitter
  • Visit Neurology on YouTube
  • Neurology
  • Neurology: Clinical Practice
  • Neurology: Education
  • Neurology: Genetics
  • Neurology: Neuroimmunology & Neuroinflammation
  • AAN.com
  • AANnews
  • Continuum
  • Brain & Life
  • Neurology Today

Wolters Kluwer Logo

Neurology | Print ISSN:0028-3878
Online ISSN:1526-632X

© 2023 American Academy of Neurology

  • Privacy Policy
  • Feedback
  • Advertise